Skip to Content
Merck
All Photos(3)

Key Documents

SML0569

Sigma-Aldrich

RO-3306

≥98% (HPLC), powder, CDK1 inhibitor

Synonym(s):

(5Z)-5-Quinolin-6-ylmethylene-2-[(thiophen-2-ylmethyl)-amino]-thiazol-4-one, 5-(6-Quinolinylmethylene)-2-[(2-thienylmethyl)amino]-4(5H)-thiazolone

Sign Into View Organizational & Contract Pricing


About This Item

Empirical Formula (Hill Notation):
C18H13N3OS2
CAS Number:
Molecular Weight:
351.45
MDL number:
UNSPSC Code:
12352200
PubChem Substance ID:
NACRES:
NA.77

product name

RO-3306, ≥98% (HPLC)

Quality Level

Assay

≥98% (HPLC)

form

powder

color

off-white to brown

solubility

DMSO: 5 mg/mL, clear

storage temp.

2-8°C

SMILES string

O=C1N=C(NCC2=CC=CS2)S/C1=C\C3=CC4=C(C=C3)N=CC=C4

InChI

1S/C18H13N3OS2/c22-17-16(24-18(21-17)20-11-14-4-2-8-23-14)10-12-5-6-15-13(9-12)3-1-7-19-15/h1-10H,11H2,(H,20,21,22)/b16-10-

InChI key

XOLMRFUGOINFDQ-YBEGLDIGSA-N

Application

RO-3306 has been used:
  • To study the significance of CA4-mediated cytotoxicity in mitotic arrest
  • In cell cycle synchronization to conduct a study on proteomics
  • As a CDK1 inhibitor, to prevent early mitotic entry

Biochem/physiol Actions

CDK1 (cyclin dependent kinase 1) is considered to be the “master switch” in cell division, which maintains the mitotic state of cells.
RO-3306 is a selective ATP-competitive inhibitor of CDK1. It inhibites CDK1 cyclin B1 activity with Ki of 35 nM, nearly 10-fold selectivity relative to CDK2/cyclin E and over 50-fold relative to CDK4/cyclin D. RO-3306 has been used to cause cell cycle arrest at the G2/M boundary.

Features and Benefits

This compound is featured on the CDKs page of the Handbook of Receptor Classification and Signal Transduction. To browse other handbook pages, click here.

Storage Class Code

11 - Combustible Solids

WGK

WGK 3

Flash Point(F)

Not applicable

Flash Point(C)

Not applicable


Certificates of Analysis (COA)

Search for Certificates of Analysis (COA) by entering the products Lot/Batch Number. Lot and Batch Numbers can be found on a product’s label following the words ‘Lot’ or ‘Batch’.

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Tamara B Garcia et al.
Leukemia research, 64, 30-33 (2017-11-28)
Inhibition of WEE1 is emerging as a promising chemosensitization strategy in many cancers including acute leukemia. Our lab and others have demonstrated that a small-molecule inhibitor of WEE1, AZD1775, sensitizes acute leukemia cells to cytarabine; however, a mechanism of combinatorial
Selective small-molecule inhibitor reveals critical mitotic functions of human CDK1.
Vassilev L T, et al.
Proceedings of the National Academy of Sciences of the USA, 103(28), 10660-10665 (2006)
Structurally simplified biphenyl combretastatin A4 derivatives retain in vitro anti-cancer activity dependent on mitotic arrest.
Tarade D, et al.
PLoS ONE, 12(3), e0171806-e0171806 (2017)
BRCA2 suppresses replication stress-induced mitotic and G1 abnormalities through homologous recombination.
Feng W and Jasin M
Nature Communications, 8(1), 525-525 (2017)
Visualization of human karyopherin beta-1/importin beta-1 interactions with protein partners in mitotic cells by co-immunoprecipitation and proximity ligation assays.
Francesco L, et al.
Scientific Reports, 8(1), 1850-1850 (2018)

Articles

Review properties, activators and inhibitors, and available products for researching cyclin-dependent kinases (CDKs).

Review properties, activators and inhibitors, and available products for researching cyclin-dependent kinases (CDKs).

Review properties, activators and inhibitors, and available products for researching cyclin-dependent kinases (CDKs).

Review properties, activators and inhibitors, and available products for researching cyclin-dependent kinases (CDKs).

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service